Lyell Immunopharma (LYEL) Expected to Release Earnings on Tuesday

Lyell Immunopharma (NASDAQ:LYEL) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Lyell Immunopharma to announce earnings of ($2.0243) per share and revenue of $0.0050 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting analysts’ consensus estimates of ($1.10). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%. On average, analysts expect Lyell Immunopharma to post $-8 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Lyell Immunopharma Stock Performance

Shares of LYEL traded up $0.73 during trading hours on Tuesday, hitting $13.60. The stock had a trading volume of 35,689 shares, compared to its average volume of 124,545. The firm has a market cap of $333.30 million, a P/E ratio of -0.98 and a beta of -0.04. The company’s fifty day simple moving average is $13.67 and its 200 day simple moving average is $19.24. Lyell Immunopharma has a 12-month low of $9.28 and a 12-month high of $45.00.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Zacks Research upgraded Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Lyell Immunopharma in a research note on Tuesday, June 9th. Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a research report on Thursday, April 30th. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a research report on Tuesday, June 9th. Finally, Citizens Jmp reaffirmed a “market outperform” rating and set a $34.00 price target on shares of Lyell Immunopharma in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $43.20.

Institutional Trading of Lyell Immunopharma

Large investors have recently modified their holdings of the business. AQR Capital Management LLC boosted its holdings in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after purchasing an additional 154,327 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Lyell Immunopharma by 204.2% in the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after purchasing an additional 443,614 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Lyell Immunopharma during the 2nd quarter valued at approximately $258,000. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma during the second quarter worth approximately $94,000. Finally, Orbimed Advisors LLC bought a new stake in shares of Lyell Immunopharma in the second quarter worth $457,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.